Extended-field Proton Therapy for Cervical Cancer

Официальное название

Proton Therapy in Extended-field Irradiation for Cervical Cancer

Обзор

Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.

Подробное описание

This study is a prospective, observational cohort study designed to evaluate the effects of proton therapy and photon therapy in patients with stage IIIC1 or IIIC2 cervical cancer undergoing extended-field radiotherapy. Primary data collection will include clinical outcomes, radiotherapy-related toxicities, lymphocyte counts, and immune cell subsets (e.g., CD4, CD8, CD19, and CD16+56), measured at baseline, during treatment, and post-treatment. Secondary data collection will involve tissue banking for future translational research projects, including serum, plasma, and whole blood for DNA analysis.

The study will be conducted in two tertiary cancer centers (CGMH and NTUCC), with individual patient participation proton or photon treatment approximately 9 weeks, followed by an additional five years for long-term follow-up to assess survival outcomes and late toxicities. This design enables robust comparison of the therapeutic impact of proton and photon therapies on clinical and immunological endpoints, providing evidence to guide personalized treatment decisions in cervical cancer.

Вмешательства

• Лучевая терапия Proton extended field radiation therapy
  Proton extended field radiation therapy
• Лучевая терапия Photon extended field radiation therapy
  Photon extended field radiation therapy

Первичные конечные точки

• Lymphocyte Counts [Срок оценки: Baseline; Weeks 3-5 of radiotherapy; 2 weeks after radiotherapy completion]
• Immune Cell Subsets [Срок оценки: Baseline; Weeks 3-5 of radiotherapy; 2 weeks after radiotherapy completion]

Вторичные конечные точки (2)

• Radiotherapy-Related Toxicities [Срок оценки: Follow-up for five years]
• Survival outcomes [Срок оценки: Follow-up for five years]

Критерии участия

Критерии включения

• Histologically confirmed cervical cancer, stage ≥ IIIC.
• Age between 20 and 85 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Eligible for extended-field radiotherapy as determined by the treating physician.
• Induction chemotherapy with paclitaxel and carboplatin is allowed if the duration is ≤ 6 weeks or ≤ 2 cycles.
• RT alone, or concurrent single-agent chemotherapy with weekly cisplatin or carboplatin during radiation therapy is allowed, while the use of any other concurrent antineoplastic agents is prohibited.
• Consolidative chemotherapy or immunotherapy after radiation therapy is allowed.

Критерии исключения

• Prior history of pelvic or abdominal radiotherapy.
• Presence of distant metastases or other active malignancies within the past 5 years, excluding non-melanoma skin cancer.
• Severe comorbid conditions, such as uncontrolled diabetes, cardiovascular disease, or autoimmune disorders, that may interfere with treatment or study participation.
• Pregnancy or breastfeeding at the time of enrollment.
• Psychiatric or social conditions that would limit compliance with study requirements or follow-up.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Тайвань · 2 центра

• National Taiwan University Hospital — Taipei
• Chang Gung Memorial Hospital — Taoyuan

Идентификаторы

NCT: NCT07298642 · 202502003RINB · TGOG7001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗